Fibrocell Science Inc (NASDAQ:FCSC) had its price target boosted by HC Wainwright from $5.70 to $7.60 in a research note issued to investors on Tuesday morning, Marketbeat reports. The firm currently has a buy rating on the stock.

Several other research firms have also recently weighed in on FCSC. Zacks Investment Research cut shares of Fibrocell Science from a buy rating to a hold rating in a report on Wednesday, July 19th. ValuEngine upgraded shares of Fibrocell Science from a sell rating to a hold rating in a report on Thursday, July 20th. Finally, Canaccord Genuity reiterated a buy rating and issued a $7.00 price target (up previously from $3.00) on shares of Fibrocell Science in a report on Monday, September 11th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and three have issued a buy rating to the stock. The company has a consensus rating of Hold and an average price target of $5.21.

Fibrocell Science (NASDAQ:FCSC) traded down 2.55% during midday trading on Tuesday, reaching $3.06. 110,304 shares of the company’s stock were exchanged. Fibrocell Science has a 1-year low of $1.57 and a 1-year high of $4.64. The stock’s market cap is $45.03 million. The firm’s 50-day moving average is $2.94 and its 200 day moving average is $2.67.

Fibrocell Science (NASDAQ:FCSC) last released its quarterly earnings results on Wednesday, August 9th. The company reported ($0.31) earnings per share for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.31). Fibrocell Science had a negative net margin of 4,307.60% and a negative return on equity of 293.07%. Equities analysts anticipate that Fibrocell Science will post ($2.17) earnings per share for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: “HC Wainwright Increases Fibrocell Science Inc (FCSC) Price Target to $7.60” was first reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this story on another domain, it was illegally stolen and reposted in violation of US and international trademark and copyright laws. The legal version of this story can be read at

A hedge fund recently raised its stake in Fibrocell Science stock. Creative Planning increased its holdings in shares of Fibrocell Science Inc (NASDAQ:FCSC) by 395.3% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 61,090 shares of the company’s stock after purchasing an additional 48,755 shares during the quarter. Creative Planning owned approximately 0.42% of Fibrocell Science worth $245,000 as of its most recent SEC filing. 54.70% of the stock is currently owned by institutional investors.

About Fibrocell Science

Fibrocell Science, Inc is an autologous cell and gene therapy company. The Company is focused on discovering and developing localized therapies for diseases affecting the skin, connective tissue and joints. Its product candidate, azficel-T, is in development to treat patients suffering from vocal cord scarring that is either idiopathic or age-related.

Receive News & Stock Ratings for Fibrocell Science Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fibrocell Science Inc and related stocks with our FREE daily email newsletter.